+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers

Arquivos de Neuro-Psiquiatria 71(9b): 689-692

Cognitive impairment and major depressive disorder (MDD) are common HIV-1 central nervous system (CNS) complications. Their frequencies in AIDS patients are 36% and 45%, respectively. The diagnoses of HIV cognitive impairment are made by clinical criteria, no single laboratory test or biomarker establishes the diagnosis. Factors of indirect neuronal injury related with the pathophysiology of the HIV infection in the CNS, are the factors studied as biomarkers. In the present no biomarker is established to the diagnosis of HIV cognitive impairment, much still needs to be done. We review in this paper some biomarkers in cerebrospinal fluid that could be valuable to the diagnosis of HIV cognitive impairment. Diagnosing depression in the context of HIV can be challenging, to identify a biomarker that could help in the diagnosis would be very important, although MDD risks and neurobiology are still poorly understood.

(PDF emailed within 0-6 h: $19.90)

Accession: 052159634

Download citation: RISBibTeXText

PMID: 24141506

DOI: 10.1590/0004-282X20130152

Related references

Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics 14(6): 499-514, 2017

Cognitive impairment in major depressive disorder and severe depressive episode with psychotic symptoms. European Psychiatry 41: S143-S144, 2017

Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease 58(3): 939-950, 2017

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Neuro-Degenerative Diseases 16(1-2): 69-76, 2016

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. Journal of Alzheimer's Disease 2019, 2019

Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurology 71(6): 742-751, 2014

Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. Journal of Alzheimer's Disease 19(1): 301-309, 2010

Cognitive impairment in major depressive disorder. Cns Spectrums 2018: 1-8, 2018

Major depressive disorder and cognitive impairment. Journal of Psychiatry and Neuroscience 39(5): E36-E37, 2015

Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. Journal of Alzheimer's Disease 30(4): 767-778, 2013

Cerebrospinal Fluid Biomarkers and Cerebral Morphometry in Mild Cognitive Impairment. 2011

Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment. Journal of Cerebral Blood Flow and Metabolism 37(3): 1006-1013, 2016

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Comprehensive Psychiatry 68: 34-39, 2017

Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects. Alzheimer's Research and Therapy 7(1): 58, 2016

Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 69(9): 1132-1138, 2014